http://www.alchemia.com.au/IRM/Company/ShowPage.aspx?CPID=1299&PageName=ABN%20AMRO%20Morgans
Alchemia 22 August 2008
Approaching finish line?
Despite share price underperformance, ACL has a number of key milestones looming
on the horizon. These include filing for market approval of its generic synthetic
heparin, which all going to plan is due to be launched in the US in 1HCY09.
Company data, ABN AMRO Morgans forecasts
year to Jun, fully diluted
A$15.6m in cash at 30 June 08
ACL reported a net loss of A$10.9m, compared to a loss of A$12.9m in the pcp and better than our
forecast loss of A$12.7m. This included total grant income of A$1.3m for the period, interest
income of A$1.3m and operating expenditure of A$14m. R&D expense has declined 43% to
A$3.2m due to the assumption of fondaparinux manufacturing costs by Dr Reddys. The net
operating cash outflow was A$8.4m. Cash at year end was A$15.6m.
Synthetic heparin on track for market launch in 1HCY09
ACL’s fondaparinux is a generic version of Arixtra, which is marketed by GSK. Together with
manufacturing and marketing partner Dr Reddy’s, ACL has now completed the first commercial
scale manufacture of generic fondaparinux, together with the required documentation for the filing
of an Abbreviated New Drug Application (ANDA) with the US FDA. Depending on review time at
the FDA, market launch is anticipated in 1HCY09. In our model we have first sales occurring from
FY10. ACL will be the only generic version of fondaparinux available; we note that generics are
generally priced at a small discount to the branded version and typically secure 40-50% of the
prescription market share.
Forecast revised to reflect a more conservative view on product launch
While ACL has the support of a strong partner in Dr Reddy’s, market launch of a new product is
complex. To reflect this, we have taken a more conservative view on penetration rates, with
forecast changes detailed over page. In FY10 NPAT has decreased 75% and in FY11 by 48%.
Investment view - Buy in anticipation of market launch
Our milestone table is contained overleaf. Our DCF valuation is A$1.17 (was A$1.52). We have set
our target price at A$0.59 (was A$1.06), a 50% discount (was 30%) to reflect where we see the
share price trading in six months. The downside risk to our target price relates to the acceptance of
Arixtra as an alternative to Lovenox.
Near-term catalysts to watch
We have identified a number of upcoming catalysts, which, if achieved should drive ACLs share
price closer to our target price.
Table 1 : Milestone Table
Estimated date Milestone Expected catalyst
2HCY08 Arixtra ACS approval Positive
2HCY08 Submit NADA for fondaparinux Positive
1HCY09 Approval of generic fondaparinux (synthetic heparin) Positive
Jul-09 Market launch of generic fondaparinux (synthetic heparin) Major positive
- Forums
- ASX - By Stock
- TSN
- abn amro say buy acl
abn amro say buy acl
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable